Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis
Clinical and Molecular Hepatology. 2022;28(2):177-180 
Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update
Gut and Liver. 2021;15(5):666-676
Tumor necrosis factor-α and interleukin-6 bioactivities in the ascitic fluid of patients with alcoholic liver cirrhosis
Gastroenterology. 1995;108(4):A1128
Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
Gut and Liver. 2021;15(5):641-642
Depressed monocyte production of interleukin-1 and tumor necrosis factor-alpha in patients with alcoholic liver cirrhosis
Liver. 2008;9(5):302-306
Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
Gut and Liver. 2022;16(4):501-502
Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis
Gut and Liver. 2021;15(6):793-794
Causes of Sarcopenia in Liver Cirrhosis
Clinical Liver Disease. 2019;14(5):167-170
Elevated serum tumor necrosis factor-α and soluble tumor necrosis factor receptors correlate with aberrant energy metabolism in liver cirrhosis
Nutrition. 2010;26(3):269-275
Anti-Tumor Necrosis Factor Therapy in Intestinal Beh Ccedil;et rsquo;s Disease
Gut and Liver. 2018;12(6):623-632